MSH2 and prostate cancer: These results were recently confirmed by a study conducted by Grindedal et al [7] who found statistically significant increased incidence of prostatic cancer among MSH2 and MSH6 carriers, where the standardized incidence ratio was as high as 13 and 13.74, respectively, which also showed aggressive behaviour.